No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Care Facilities
Operating as an investment holding firm, China Resources Medical Holdings Company Limited delivers a spectrum of healthcare services, encompassing general medical care, hospital administration, and advisory functions within the People's Republic of China. Its business activities are structured into three main divisions: hospitals it directly owns, facilities managed under Invest-Operate-Transfer (IOT) or Operate-Transfer (OT) agreements, and other ancillary operations. The company further provides group purchasing solutions and various services derived from its hospital network. A key component of its strategy involves managing and operating external hospitals and clinics through its IOT model. Additionally, the enterprise is active in the sale of pharmaceuticals, medical apparatus, medical consumables, and specialized equipment. Established in 2007, the company adopted its current name, China Resources Medical Holdings Company Limited, in October 2018, having previously been known as China Resources Phoenix Healthcare Holdings Company Limited. Its corporate headquarters are located in Beijing, People's Republic of China.
www.crmedical.hkNo one on the platform currently holds 1515.HK.
No tracked institution reports a position in 1515.HK as of their last filing.
No one on the platform has traded 1515.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 4.8% | 6.9% | — | — | — | |
| Rev. Growth % | -6.9% | 27.2% | ||||
| Profit Margin % | 5.4% | 5.3% | 0.1% | |||
| Free Cash Flow Margin % | 9.2% | 7.9% | 11.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $9.8B | +9.3% | $0.40 | $0.39–$0.40 | — | 1 |
| 2027 | $10.0B | +2.0% | $0.41 | $0.40–$0.42 | — | 1 |
| 2028 | $10.0B | -0.5% | $0.43 | $0.42–$0.44 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| +2.29% |
| $7.1B |
| — |
| 3880.HKMedtide Inc. | $18.93 | +0.37% | $2.7B | — |
| 6660.HKAIM Vaccine Co., Ltd. | $1.59 | -4.49% | $2.0B | — |
Source: Financial Modeling Prep · peers by sector/industry